Calmodulin-dependent cyclic nucleotide phosphodiesterase (PDE1)

Cellular and Molecular Life Sciences

Volumn 55, Issue 8-9, 1999, Pages 1164-1186

  Kakkar, R ^a   Raju, R V S ^a   Sharma, R K ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Calcium; Calmodulin; Calpains; Inhibitors; Phosphodiesterase; Protein kinase

Indexed keywords

ANTIPARKINSON AGENT; CALCIUM ION; CALMODULIN; CYCLIC AMP; CYCLIC NUCLEOTIDE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; DIHYDROPYRIDINE; ISOENZYME; TRANSCRIPTION FACTOR;

GINSENG; HUMAN; NONHUMAN; PHYSIOLOGY; PROTEIN DEGRADATION; REVIEW; SIGNAL TRANSDUCTION;

EID: 0032777242     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000180050364     Document Type: Review

References (179)

1. 2 + /calmodulin-dependent cyclic nucleotide phosphodiesterase. In: Phosphodiesterase inhibitors, pp. 65-79, Dent G., Rabe K. and Schudt C. (eds), Academic Press, New York
2. 2 Beavo J. A. (1995) Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev. 75: 725-743
3. 3 Manganiello V. C., Murata T., Taira M., Belfrage P. and Degerman E. (1995) Diversity in cyclic nucleotide phosphodiesterase isoenzyme families. Arch. Biochem. Biophys. 322: 1-13
4. 4 Wang J. H., Sharma R. K. and Mooibrock M. J. (1990) Calmodulin-stimulated cyclic nucleotide phosphodiesterase. Mol. Pharmacol. Cell. Reg. 2: 19-59
5. 5 Sharma R. K., Mooibroek M. J. and Wang J. H. (1988) Calmodulin-stimulated cyclic nucleotide phosphodiesterase isozymes. In: The Molecular Aspects of Cellular Regulation, vol. 5, pp. 265-295, Cohen P. and Klee C. B. (eds), Elsevier, Amsterdam
6. 6 Wells J. N. and Hardman J. G. (1977) Cyclic nucleotide phosphodiesterases. Adv. Cyclic Nucleotide Res. 8: 119-143
7. 7 Sutherland E. W. and Roll T. W. (1958) Fractionation and characterization of cyclic adenine ribonucleotide formed by tissue particles. J. Biol. Chem. 232: 1077-1091
8. 8 Appleman M. M., Thompson W. J. and Russell T. R. (1973) Cyclic nucleotide phosphodiesterases. Adv. Cyclic Nucleotide Res. 3: 65-98
9. 9 Appleman M. M., Ariano M. A., Takemoto D. J. and Whitson R. H. (1982) Cyclic nucleotide phosphodiesterases. In: Handbook of Experimental Pharmacology, vol. 58.1, pp. 261-299, Nathansons J. A. and Kebabian J. W. (eds), Springer-Verlag Berlin, New York
10. 10 Beavo J. A., Hansen R. S., Harrison S. A., Hurwitz R. L., Martins T. J. and Mumby M. C. (1982) Identification and properties of cyclic nucleotide phosphodiesterases. Mol. Cell. Endocrinol. 28: 387-410
11. 11 Beavo J. A., Conti M. and Heaslip R. J. (1994) Multiple cyclic nucleotide phosphodiesterases. Mol. Pharmacol. 75: 399-405
12. 12 Loughney K., Martins T. J., Harris E. A., Sadhu K., Hicks J. B., Sonnenburg W. K. et al. (1996) Isolation and characterization of cDNAs corresponding to two human calcium, calmodulin-regulated, 3′,5′-cyclic nucleotide phosphodiesterases. J. Biol. Chem. 271: 796-806
13. 13 Yan C., Zhao A. Z., Bentley J. K. and Beavo J. A. (1996) The calmodulin-dependent phosphodiesterase gene PDEIC encodes several functionally different splice variants in a tissue-specific manner. J. Biol. Chem. 271: 25699-25706
14. 14 Yu J., Wolda S. L., Frazier A. L. B., Harris E. A. S., McCaw K. N., Farrell C. A. et al. (1997) Identification and characterization of a human calmodulin-stimulated phosphodiesterase PDE1B1. Cell Signal. 9: 519-529
15. 15 Kakiuchi S. and Yamazaki R. (1970) Calcium-dependent phosphodiesterase activity and its activating factor (PAF) from brain studies on cyclic 3′:5′-nucleotide phosphodiesterase. Biochem. Biophys. Res. Commun. 41: 1104-1110
16. 16 Kakiuchi S., Yamazaki R. and Nakajima H. (1970) Properties of a heat-stable phosphodieterase activating factor isolated from brain extract. Proc. Jap. Acad. 46: 587-592
17. 17 Teo T. S. and Wang J. H. (1973) Mechanism of activation of cyclic idenosine 3′:5′-monophosphate phosphodiesterase from bovine heart by calcium ions. J. Biol. Chem. 248: 5950-5955
18. 18 Cheung W. Y. (1970) Cyclic 3′:5′-nucleotide phosphodiesterase. Determination of an activator. Biochem. Biophys. Res. Commun. 38: 533-538
19. 19 Cheung W. Y. (1971) Cyclic 3′:5′-nucleotide phosphodiesterase. J. Biol. Chem. 246: 2859-2869
20. 20 Wang J. H., Teo T. S., Ho H. C. and Stevens F. C. (1975) Bovine heart protein activator of cyclic nucleotide phosphodiesterases. Adv. Cyclic Nucleotide Res. 5: 179-194
21. 21 Morrill M. E., Thompson S. T. and Stellwagen E. (1979) Purification of a cyclic nucleotide phosphodiesterase from bovine brain using blue dextran-Sepharose chromatography. J. Biol. Chem. 254: 4371-4374
22. 22 Sharma R. K., Wang T. H, Wirch E. and Wang J. H. (1980) Purification and properties of bovine brain calmodulin-dependent cyclic nucleotide phosphodiesterase. J. Biol. Chem. 255: 5916-5923
23. 23 Kincaid R. L. and Vaughan M. (1983) Affinity chromatography of brain cyclic nucleotide phosphodiesterase using 3-(2-pyridyldithiol) propionyl-substituted calmodulin linked to thiol-Sepharose. Biochemistry 22: 826-830
24. 24 Kincaid R. L., Manganiello V. C., Odya C. E., Osborne J. C., Smith-Coleman I. E., Danello M. A. et al. (1984) Purification and properties of calmodulin-stimulated phosphodiesterase from mammalian brains. J. Biol. Chem. 259: 5158-5166
25. 2+ /calmodulin-stimulated cyclic GMP phosphodiesterase from bovine brain. Biochemistry 24: 672-678
26. 2+ -sensitive phosphodiesterase purified from bovine heart. Biochemistry 18: 2820-2825
27. 27 Hansen R. S. and Beavo J. A. (1982) Purification of two calcium-calmodulin-dependent forms of cyclic nucleotide phosphodiesterase by using conformation-specific monoclonal antibody chromatography. Proc. Natl. Acad. Sci. USA 79: 2788-2792
28. 28 Sharma R. K. (1991) Phosphorylation and characterization of bovine heart calmodulin-dependent phosphodiesterase. Biochemistry 30: 5964-5968
29. 29 Sharma R. K., Tan Y. and Raju R. V. S. (1997) Calmodulin-dependent cyclic nucleotide phosphodiesterase from bovine eye; high calmodulin affinity isozyme immunologically related to the brain 60 kDa isozyme. Arch. Biochem. Biophys. 339: 40-46
30. 2 + -dependent cyclic nucleotide phosphodiesterase. Biochemistry 18: 722-729
31. 31 Sharma R. K. and Wang J. H. (1986) Purification and characterization of bovine lung calmodulin-dependent cyclic nucleotide phosphodiesterase. An enzyme containing calmodulin as a subunit. J. Biol. Chem. 261: 14160-14166
32. 32 Weber K. and Osborn M. (1969) The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis. J. Biol. Chem. 244: 4406-4412
33. 33 Laemmli U. K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685
34. 34 Sharma R. K., Adachi A. H., Adachi K. and Wang J. H. (1984) Demonstration of bovine brain calmodulin-dependent cyclic nucleotide phosphodiesterase isozyme by monoclonal antibodies. J. Biol. Chem. 259: 9248-9254
35. 35 Hansen R. S. and Beavo J. A. (1986) Differential recognition of calmodulin-enzyme complexes by a confirmation specific anti-calmodulin monoclonal antibody. J. Biol. Chem. 261: 14636-14645
36. 2 + -dependent modulator protein as the fourth subunit of rabbit skeletal muscle phosphorylase kinase. FEBS Lett. 92: 287-293
37. 37 Sonnenburg W. K., Seger D., Kwak K. S., Huang J., Charbonneau H. and Beavo J. A. (1995) Identification of inhibitory and calmodulin-binding domains of the PDE1A1 and PDE1A2 calmodulin-stimulated cyclic nucleotide phosphodiesterase. J. Biol. Chem. 270: 30989-31000
38. 38 Rossi P., Giorgi M., Geremia R. and Kincaid R. L. (1988) Testis-specific calmodulin-dependent phosphodiesterase. A distinct high affinity cAMP isozyme immunologically related to brain calmodulin-dependent cGMP phosphodiesterase. J. Biol. Chem. 263: 15521-15527
39. 2 +. Proc. Natl. Acad. Sci. USA 70: 3526-3530
40. 40 Sharma R. K. and Kalra J. (1994) Characterization of calmodulin-dependent cyclic nucleotide phosphodiesterase isozymes. Biochem. J. 299: 97-100
41. 41 Wasco W. M. and Orr G. A. (1984) Function of calmodulin in mammalian sperm: presence of a calmodulin-dependent cyclic nucleotide phosphodiesterase associated with demembranated rat caudal epididymal sperm. Biochem. Biophys. Res. Commun. 118: 636-642
42. 42 Weishaar R. E., Burrows S. D., Kobylarz D. C., Quade M. M. and Evans D. B. (1986) Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and in platelets. Isolation, characterization and effects of various reference phosphodiesterase inhibitors and cardiotonic agents. Biochem. Pharrnacol. 35: 787-800
43. 43 Ho H. C., Teo T. S., Desai R. and Wang J. H. (1976) Catalytic and regulatory properties of two forms of bovine heart cyclic nucleotide phosphodiesterase. Biochim. Biophys. Acta. 429: 461-473
44. 44 Reeves M. L., Leigh B. K. and England P. J. (1987) The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Biochem. J. 241: 535-541
45. 45 Keravis T. M., Duemler B. H. and Wells J. M. (1986) Calmodulin-sensitive phosphodiesterae of porcine cerebral cortex: kinetic behaviour, calmodulin activation and stability. J. Cyclic Nucleotide Protein Phosphor. Res. 11: 365-372
46. 46 Vandermeers A., Vandermeers-Piret M. C., Rathe J. and Christophe J. (1983) Purification and kinetic properities of two soluble forms of calmodulin-dependent cyclic nucleotide phosphodiesterase from rat pancreas. Biochem. J. 211: 341-347
47. 47 Purvis K., Olsen A. and Hansson V. (1981) Calmodulin-dependent cyclic nucleotide phosphodiesterase in the immature rat testis. J. Biol. Chem. 256: 11434-11441
48. 2 + to calmodulin for activation. Proc. Natl. Acad. Sci. USA 78: 871-874
49. 49 Mutus B., Karuppiah N., Sharma R. K. and MacManus J. H. (1985) The differential stimulation of brain and heart cyclic-AMP phosphodiesterase by oncomodulin. Biochem. Biophys. Res. Commun. 131: 500-506
50. 50 Klee C. B. and Vanaman T. C. (1982). Calmodulin. Adv. Prot. Chem. 35: 213-321
51. 51 Olwin B. B., Keller C. H. and Storm D. R. (1984) Calcium-dependent and calcium-independent affinities of calmodulin for calmodulin-binding proteins determined by fluorescence techniques. Adv. Cyclic Nucleotide Protein Phosphor. Res. 16: 227-243
52. 52 Rasmussen H. (1970) Cell communication, calcium ion and cyclic adenosine monophosphate. Science 170: 404-412
53. 53 Berridge M. J. (1975) The interaction of cyclic nucleotides and calcium in the control of cellular activity. Adv. Cyclic Nucleotide Res. 6: 1-98
54. 54 Berridge M. J., Bootman M. D. and Lipp P. (1998) Calcium a life and death signal. Nature 395: 645-648
55. 55 Rasmussen H. and Goodman D. B. (1977) Relationship between calcium and cyclic nucleotides in cell activation. Physiol. Rev. 57: 421-509
56. 56 Krebs E. G. and Beavo J. A. (1979) Phosphorylation and dephosphorylation of enzymes. Annu. Rev. Biochem. 48: 923-959
57. 57 Sharma R. K. and Kalra J. (1994) Molecular interaction between cAMP and calcium in calmodulin-dependent cyclic nucleotide phosphodiesterase system. Clin. Invest. Med. 17: 374-382
58. 2+ /calmodulin-dependent protein kinase. Life Sci. 35: 493-499
59. 59 Sharma R. K. and Wang J. H. (1985) Differential regulation of bovine brain calmodulin-dependent cyclic nucleotide phosphodiesterase isozyme by cyclic AMP-dependent protein kinase and calmodulin-dependent phosphatase. Proc. Natl. Acad. Sci. USA 82: 2603-2607
60. 60 Florio V. A., Sonnenburg W. K., Johnson R., Kwak K. S., Jensen G. S., Walsh K. A. et al. (1994) Phosphorylation of the 61-kDa calmodulin-stimulated cyclic nucleotide phosphodiesterase at serine 120 reduces its affinity for calmodulin. Biochemistry 33: 8948-8954
61. 61 Sharma R. K. and Wang J. H. (1986) Regulation of 63 kDa subunit containing isozyme of bovine brain calmodulin-dependent cyclic nucleotide phosphodiesterase by a calmodulin-dependent protein kinase. J. Biol. Chem. 261: 1322-1328
62. 2 +/ calmodulin-dependent protein kinase II. J. Biol. Chem. 264: 10884-10887
63. 63 Zhang G. Y., Wang J. H. and Sharma R. K. (1993) Purification and characterization of bovine brain calmodulin-dependent protein kinase II. The significance of autophosphorylation in the regulation of 63 kDa calmodulin-depndent cyclic nucleotide phosphodiesterase isozyme. Mol. Cell Biochem. 122: 159-169
64. 64 Sharma R. K. and Wang J. H. (1986) Regulation of cAMP concentration by calmodulin-dependent cyclic nucleotide phosphodiesterase. Biochem. Cell Biol. 64: 1072-1080
65. 65 Sharma R. K. (1995) Signal transduction: regulation of cAMP concentrations in cardiac muscle by calmodulin-dependent cyclic nucleotide phosphodiesterase. Mol. Cell. Biochem. 149/150: 241-247
66. 66 Brostrom C. O., Hunag Y. C., Breckenridge B. M. and Wolff D. J. (1975) Identification of a calcium-binding protein as a calcium-dependent regulator of brain adenylate cyclase. 72: 64-67
67. 2 + -dependent regulation of guinea pig brain adenylate cyclase. J. Biol. Chem. 255: 4176-4181
68. 2 + /calmodulin-dependent protein kinase from rat brain. Biochemistry 23: 5495-5504
69. 69 Yamauchi T. and Fujisawa H. (1985) Self-regulation of calmodulin-dependent protein kinase II and glycogen synthase kinase by autophosphorylation. Biochim. Biophys. Res. Commun. 129: 213-219
70. 2+ independent activities and kinetic parameters. J. Biol. Chem. 262: 8051-8055
71. 2 + triggered molecular switch. Cell 44: 861-870
72. 2 + /calmodulin-dependent protein kinase II. Proc. Natl. Acad. Sci. USA 83: 4253-4257
73. 2+ / (calmodulin)-dependent protein kinase II by an autophosphorylation mechanism. J. Biol. Chem. 261: 8581-8584
74. 74 Zhang G. Y., Wang J. H. and Sharma R. K. (1993) Bovine brain calmodulin-dependent protein kinase II: molecular mechanisms of autophosphorylation. Biochem. Biophys. Res. Commun. 191: 669-674
75. 75 Woods N. M., Cutherbertson K. S. R. and Cobbold P. H. (1986) Repetitive transient rises in cytoplasmic free calcium in hormone-stimulated hepatocytes. Nature 319: 600-602
76. 76 Woods N. M., Cutherbertson K. S. R. and Cobbold P. H. (1987) Agonist-induced oscillations in cytoplasmic free calcium concentration in single rat hepatocytes. Cell Calcium 8: 79-100
77. 2+ transients in stimulated hepatocytes and A10 cells measured using fura-2 and fluorescent videomicroscopy. J. Biol. Chem. 263: 4569-4575
78. 78 Ouimet C. C., McGuiness T. L. and Greengard P. (1984) Immunocytochemical localization of calcium/calmodulin-dependent protein kinase II in rat brain. Proc. Natl. Acad. Sci. USA 81: 5604-5608
79. 79 Saitoh Y., Yamamato H., Fukunaga K., Matsukado Y. and Miyamoto E. (1987) Inactivation and reactivation of the multifunctional calmodulin-dependent protein kinase from brain by autophosphorylation and dephosphorylation: involvement of protein phosphatases from brain. J. Neurochem. 99: 1286-1292
80. 2+ activated and pH sensitive cAMP phosphodiesterase in the nervous system of the mollusc Pleurobranchaeu. Brain Res. 271: 371-374
81. 81 Bronstein J. M., Farber D. B. and Wasterlain C. G. (1993) Regulation of type-II calmodulin kinase: functional implications. Brain Res. Rev. 18: 135-147
82. 82 Huang F. L. and Glinsmann W. H. (1976) Separation and characterization of two phosphorylase phosphatase inhibitors from rabbit skeletal muscle. Eur. J. Biochem. 70: 419-426
83. 83 Hemmings H. C., Greengard P., Tung H. Y. L. and Cohen P. (1984) DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-I. Nature 310: 503-505
84. 84 Rogers S., Wells R. and Rechsteiner M. (1986) Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis. Science 234: 364-368
85. 85 Carillo S., Pariat M., Steff A. M., Jarielencontre I., Poulat F., Berta P. et al. (1996) PEST motifs are not required for rapid calpain mediated proteolysis of c-fos protein. Biochem. J. 313: 245-251
86. 86 Barnes J. A. and Gomes A. V. (1995) PEST sequences in calmodulin binding proteins. Mol. Cell. Biochem. 149-150: 17-27
87. 87 Rechsteiner M. and Rogers S. W. (1996) PEST sequences and regulation of proteolysis. Trends Biochem. Sci. 21: 267-271
88. 88 Sonnenburg W. K., Seger D. and Beavo J. A. (1993) Molecular cloning of a cDNA encoding the 61-kDa calmodulin-stimulated cyclic nucleotide phosphodiesterase. J. Biol. Chem. 268: 645-652
89. 89 Molinari M., Anagli J. and Carafoli E. (1995) PEST sequences do not influence substrate susceptibility to calpain proteolysis. J. Biol. Chem. 270: 2032-2035
90. 90 Kakkar R., Raju R. V. S. and Sharma R. K. (1998) In vitro generation of an active calmodulin-independent phosphodiesterase from brain calmodulin-dependent phosphodiesterase (PDE1A2) by m-calpain. Arch. Biochem. Biophys. 358: 320-328
91. 91 Croall D. E. and Demartino G. N. (1991) Calcium activated neutral protease (calpain) system: structure, function and regulation. Physiol. Rev. 71: 813-847
92. 92 Sorimachi H., Ishiura S. and Suzuki K. (1997) Structure and physiological function of calpains. Biochem. J. 328: 721-732
93. 93 Carafoli E. and Molinari M. (1998) Calpain: a protease in search of function. Biochem. Biophys. Res. Commun. 247: 193-203
94. 94 Tompa P., Baki A., Schad E. and Friedrich P. (1996) The calpain cascade: μ-calpain activates m-calpain. J. Biol. Chem. 271: 33161-33164
95. 95 Hamakubo T., Kannagi R., Murachi T. and Matus A. (1986) Distribution of calpain I and II in rat brain. J. Neurosci. 6: 3103-3111
96. 96 Hirai S., Kawasaki H., Yaniv M. and Suzuki K. (1991) Degradation of transcriptional factors, c-Jun and c-Fos, by calpain. FEBS Lett. 287: 57-61
97. 97 Mellgren R. L. and Carr T. C. (1983) The protein inhibitor of calcium-dependent proteases: purification from bovine heart and possible mechanism of regulation. Arch. Biochem. Biophys. 225: 779-786
98. 98 Kakkar R., Raju R. V. S., Mellgren R. L., Radhi J. A. and Sharma R. K. (1997) Cardiac high molecular weight calmodulin binding protein contains calpastatin activity. Biochemistry 36: 11550-11555
99. 99 Li J., Nixon R., Messer A., Berman S. and Bursztajn S. (1998) Altered gene expression for calpain/calpastatin system in motor neuron degeneration (Mnd) mutant mouse brain and spinal cord. Brain. Res. Mol. Brain Res. 53: 174-186
100. 100 Saido T. C., Sorimachi S. and Suzuki K. (1994) Calpain: new perspectives in molecular diversity and physiological and pathological involvement. FASEB J. 8: 814-822
101. 101 Saito K. I., Elce J. S., Hamos J. E. and Nixon R. A. (1993) Widespread activation of calcium activated neutral proteinase (calpain) in the brain in Alzeimer's disease: a potential molecular basis for neuronal degeneration. Proc. Natl. Acad. Sci. USA 90: 2628-2632
102. 102 Zhang W., Lu Q., Xie Z. J. and Mellgren R. L. (1997) Inhibition of the growth of WI-38 fibroblasts by benzyloxycarbonyl-Leu-Leu-Tyr diazomethyl ketone: evidence that cleavage of p53 by a calpain like protease is necessary for G1 to S phase transition. Oncogene 23: 255-263
103. 103 Liu Z. Q., Kunimatsu M., Yang J. P., Ozaki Y., Sasaki M. and Okamoto T. (1996) Proteolytic processing of nuclear factor-kB by calpain in vitro. FEBS Lett. 385: 109-113
104. 104 Houslay M. D. and Milligan G. (1997) Tailoring cAMP-signalling responses through isoform multiplicity. Trends. Biochem. Sci. 22: 217-224
105. 105 Montiminy M. R., Gonzalez G. A. and Yamamoto K. K. (1990) Regulation of cAMP-inducible genes by CREB. Trends Neurosci. 13: 184-188
106. 106 Kincaid R. L., Balaban C. D. and Billingsley M. L. (1992) Regional and developmental expression of calmodulin dependent cyclic nucleotide phosphodiesterase in rat brain. Adv. Sec. Mess. Phosphoprot. Res. 25: 111-122
107. 2 + signalling. Nature 374: 421-424
108. 108 Wang K. K. W., Villalobo A. and Roufogalis B. D. (1989) Calmodulin-binding proteins as calpain substrates. Biochem. J. 262: 693-706
109. 109 Elvira M., Diez J. A., Wang K. K. W. and Villalobo A. (1993) Phosphorylation of connexin-32 by protein kinase C prevents its proteolysis by μ-calpain and m-calpain. J. Biol. Chem. 268: 14294-14300
110. 110 Charbonneau H., Kumar S., Novack J. P., Blumenthal D. K., Griffin P. R., Shabanowitz J. et al. (1991) Evidence for domain organization within the 61 kDa calmodulin-dependent cyclic nucleotide phosphodiesterase from bovine brain. Biochemistry 30: 7931-7940
111. 111 Kishimoto A., Mikawa K., Hashimoto K., Yasuda I., Tanaka S., Tominaga M. et al. (1989) Limited proteolysis of protein kinase C by calcium activated neutral protease (calpain). J. Biol. Chem. 264: 4088-4092
112. 112 Banik N. L., Chou C. H., Deiber G. E., Krutzch H. C. and Hogan E. L. (1994) Peptide bond specificity of calpain: proteolysis of human myelin basic protein. J. Neurosci. Res. 37: 489-496
113. 2+ -binding protein ALG-2 and Alzheimer's disease gene ALG-3. Science 271: 521-525
114. 114 Jordan J., Galindo M. F. and Miller R. J. (1997) Role of calpain and interleukin-Iβ converting enzyme-like proteases in the β-amyloid induced death of rat hippocampal neurons in culture. J. Neurochem. 68: 1612-1621
115. 115 Prehn J. H., Bindokas V. P., Jordan J., Galindo M. F., Ghadge G. D., Roos R. P. et al. (1996) Protective effect of transforming growth factor beta 1 on beta amyloid neurotoxicity in rat hippocampal neurons. Mol. Pharmacol. 49: 319-328
116. 116 Nath R., Raser K. J., Stafford D., Hajimohammadreza I., Posner A., Allen H. et al. (1996) Non-erythroid a-spectrin breakdown by calpain and interleukin Iβ-converting enzyme like protease(s) in apoptotic cells: contributory roles of both protease families in neuronal apoptosis. Biochem. J. 319: 683-690
117. 117 Brorson J. R., Marcuccilli C. J. and Miller R. J. (1995) Delayed antagonism of calpain reduces excitoxicity in cultured neurons. Stroke 26: 1259-1267
118. 118 Nishino N., Kitamura N., Hashimoto T. and Tanaka C. (1993) Transmembrane signalling systems in the brain of patients with Parkinson's disease. Rev. Neurosci. 4: 213-222
119. 119 Kakkar R., Raju R. V. S., Rajput A. and Sharma R. K. (1996) Inhibition of bovine brain calmodulin-dependent cyclic nucleotide phosphodiesterase isozymes by deprenyl. Life Sci. 59: 337-341
120. 120 Kakkar R., Raju R. V. S., Rajput A. and Sharma R. K. (1997) Amantadine: an antiparkinsonian agent inhibits bovine brain 60 kDa calmodulin-dependent cyclic nucleotide phosphodiesterase isozyme. Brain. Res. 749: 290-294
121. 121 Hickie R. A., Thompson W. J., Strada S. J., Couture-Murillo B., Morris H. P. and Robison G. A. (1977) Comparison of cyclic adenosine 3′:5′-monophosphate and cyclic guanosine 3′:5′-monophosphate levels, cyclases and phosphodiesterases in Morris hepatomas and liver. Cancer Res. 37: 3599-3606
122. 122 Rybalkin S. D., Bornfeldt K. E., Sonnenburg W. K., Rybalkina J. G., Kwak K. S., Hanson K. et al. (1997) Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDEIC) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype. J. Clin. Invest. 100: 2611-2621
123. 123 Hickie R. A., Walker C. M. and Croll G. A. (1974) Decreased cyclic adenosine 3′:5′-monophosphate levels in Morris hepatoma 5123 1.c.(h). Biochem. Biophys. Res. Commun. 59: 167-173
124. 124 Hickie R. A., Graham M. J., Buckmeier J. A. and Meyskens F. L. Jr (1992) Comparison of calmodulin gene expression in human neonatal melanocytes and metastatic melanoma cell lines. J. Invest. Dermatol. 99: 764-773
125. 125 Wei J. W. and Hickie R. A. (1983) Decreased activities of cyclic cytidine 3′:5′-monophosphate phosphodiesterase in Morris hepatomas having varying growth rates. Int. J. Biochem. 15: 789-795
126. 126 Thompson W. J., Ross C. P., Strada S. J., Hersh E. M. and Lavis V. R. (1980) Comparative analyses of cyclic adenosine 3′:5′-monophosphate phosphodiesterase of human pheripheral blood monocytes and cultured P388D cells. Cancer Res. 40: 1955-1960
127. 127 Lal S., Raju R. V. S., Macaulay R. J. B. and Sharma R. K. (1996) Calmodulin-dependent cyclic nucleotide phosphodiesterase in human cerebral cortex and glioblastoma multiforme. Can. J. Neurol. Sci. 23: 245-250
128. 128 Lal S., Raju R. V. S. and Sharma R. K. (1998) Novel protein inhibitor of calmodulin-dependent cyclic nucleotide phosphodiesterase from glioblastoma multiforme. Neurochem. Res. 23: 533-538
129. 129 Beavo J. A. (1995) cGMP inhibition of heart phosphodiesterase: Is it clinically relevant? J. Clin. Invest. 95: 445
130. 130 Tani T., Sakurai K., Kimura Y., Ishikawa T. and Hidaka H. (1992) Pharmacological manipulation of tissue cAMP by inhibitors: effect of phosphodiesterase inhibitors on the function of platelets and vascular endothelial cells. Adv. Sec. Mess. Phosphoprot. Res. 25: 215-227
131. 131 Perry M. J. and Higgs G. A. (1998) Chemotherapeutic potential of phosphodiesterase inhibitors. Curr. Opin. Chem. Biol. 2: 472-481
132. 132 Raeburn D. and Karlsson J. A. (1997) Phosphodiesterase inhibitors: knockout drops. J. Pharm. Pharmacol. 49 (Suppl. 3): 19-24
133. 133 Meskini N., Nemoz G., Okyayuzbaklouti I., Lagarde M. and Prigent A. F. (1994) Phosphodiesterase inhibitory profile of some related xanthine derivatives pharmacologically active on the peripheral microcirculation. Biochem. Pharmacol. 47: 781-788
134. 134 Chen X. (1996) Cardiovascular protection by ginsenoides and their nitric oxide releasing action. Clin. Exp. Pharmacol. Physiol. 23: 728-732
135. 135 Takahashi M. and Tokuyama S. (1998) Pharmacological and physiological effects of ginseng on actions induced by opiods and psychostimulants. Methods Find. Exp. Clin. Pharmacol. 20: 77-84
136. 136 Sharma R. K. and Kalra J. (1994) Ginsenoides are potent and selective inhibitors of some calmodulin-dependent phosphodiesterase isozymes. Biochemistry 32: 4975-4978
137. 137 Uitti R. J., Rajput A. H., Ahlskog J. E., Offord K.P., Schroeder D. R., Ho M. M. et al. (1996) Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. Neurology 46: 1551-1556
138. 138 DeQuattro V. (1994) Individualization of therapy for hypertension in the 1990s: the role of calcium antagonists. Clin. Exp. Hypertens. 16: 853-864
139. 139 Mayer D. (1995) Pharmacokinetics and pharmacodynamics of calcium channel blockers. Vnitr. Lek. 41: 164-166
140. 140 Bostrom S-L., Ljun B., Mardh D., Forsen S. and Thulin E. (1981) Interaction of the antihyperttensive drug felodipine with calmodulin. Nature 292: 777-778
141. 141 Bostrom S. L., Westerlund C., Rochester S. and Vogel H. J. (1988) Binding of a dihydropyridine felodipine-analogue to calmodulin and related calcium binding proteins. Biochem. Pharmacol. 37: 3723-3728
142. 142 Van Belle H. (1984) The effect of drugs on calmodulin and its interaction with phosphodiesterase. Adv. Cyclic Nucleotide Protein Phosphor. Res. 17: 557-567
143. 143 Weiss B., Prozialeck W., Cimino M., Barnette M. S. and Wallace T. L. (1980) Pharmacological regulation of calmodulin. Ann. N. Y. Acad. Sci. 356: 319-345
144. 144 Prozialeck W. C. and Weiss B. (1982) Inhibition of calmodulin by phenathiazines and related drugs: structure-activity relationships. J. Pharmacol. Exp. Ther. 222: 509-516
145. 145 Roufgalis B. D. (1982) Specificity of trifluoroperazine and related phenothiazines for calcium binding proteins. In: Calcium and Cell Function, vol. 3, pp. 129-159, Chung W. Y. (ed.). Academic Press, New York
146. 146 Asano M. and Hidaka H. (1984) Biopharmacological properties of naphthalenesulfonamides as potent calmodulin antagonists. In: Calcium and Cell Function, vol. 5, pp. 123-164, Chung W. Y. (ed.), Academic press, New York
147. 147 Epstein P. M., Fiss K., Hachison R. and Andrenyak M. (1982) Interaction of calcium antagonists with cyclic AMP phosphodiesterase and calmodulin. Biochem. Biophys. Res. Commun. 105: 1142-1149
148. 148 Walsh M. P., Sutherland C. and Scott-Woo G. C. (1988) Effects of felodipine (a dihydropyridine calcium channel blockers) and analogues on calmodulin-dependent enzymes. Biochem. Pharmacol. 37: 1569-1580
149. 149 Ronea-Testoni S., Hrelia S., Hakim G. and Rossi C. A. (1985) Interaction of smooth muscle relaxant drugs with calmodulin and cyclic nucleotide phosphodiesterase. Experientia 41: 75-76
150. 150 Minocherhomjec A. M. and Roufogalis B. D. (1984) Antagonism of calmodulin and phosphodiesterase by nifedipine and related calcium entry blockers. Cell Calcium 5: 57-63
151. 151 Sharma R. K., Wang J. H. and Wu Z. (1997) Mechanism of inhibition of calmodulin-stimulated cyclic nucleotide phosphodiesterase by dihydropyridine calcium antagonists. J. Neurochem. 69: 845-850
152. 152 De La Monte S. M., Wells S. E., Hedley-Whyte E. T. and Growdon J. H. (1989) Neuropathological distinction between Parkinson's dementia and Parkinson's disease. Ann. Neurol. 26: 309-320
153. 11C-raclopride and positron emmission tomography. Ann. Neurol. 31: 184-192
154. 2 sites in Parkinson's syndrome of different etiology. Brain Res. 483: 30-38
155. 2 dopamine receptors in the efflux of cAMP from rat neostriatum. Nature 294: 366-368
156. 156 Undie A. S. and Friedman E. (1990) Stimulation of Dopamine D1 receptor enhances inositol phosphates formation in rat brain. J. Pharmacol. Exp. Ther. 253: 987-992
157. 2 + mobilization in Xenopus oocytes. Proc. Natl. Acad. Sci. USA 87: 2196-2200
158. 1 dopamine receptors are unchanged in Schizophrenic and Parkinson's disease. Eur. J. Pharmacol. 114: 235-237
159. 159 Riederer P., Rausch W. D., Birkmayer W., Jellinger K. and Danielczyk W. (1978) Dopamine sensitive adenylate cyclase activity in the caudate nucleus and adrenal medulla in Parkinson's disease and in liver cirrhosis. J. Neural. Transm. 14: 153-161
160. 160 Mcafee D. A., Schorderet M. and Greengard P. (1971) Adenosine 3′.5′-monophosphate in nervous tissue: increase associated with synaptic transmission. Science 171: 1156-1158
161. 161 Rydel R. E. and Greene L. A. (1988) cAMP analogs promote survival and neurite outgrowth in cultures of rat sympathetic and sensory neurons independently of nerve growth factor. Proc. Natl. Acad. Sci. USA 85: 1257-1261
162. 162 Brenneman D. E., Fitzgerald S. and Litzinger M. J. (1985) Neuronal survival during electrical blockade is increased by 8-bromocyclic adenosine 3′5′-monophosphate. J. Pharmacol. Exp. Ther. 233: 402-408
163. 163 Hartikka J., Staufenbiel M. and Lubert H. (1992) Cyclic AMP, but not basic FGF, increases the in vitro survival of mesencephalic dopaminergic neurons and protects them from MPP ′ -induced degeneration. J. Neurosci. Res. 32: 190-201
164. 164 Lange K. W., Riederer P. and Youdim M. B. H. (1994) Biochemical actions of 1-deprenyl (selegeline). Clin. Pharmacol. Ther. 56: 734-741
165. 165 Birkmayer W., Riederer P., Youdim M. B. H. and Linauer W. (1975) The potentiation of the antiakinetic effect after L-dopa treatment by an inhibitor of MAO-B deprenyl. J. Neural. Transm. 36: 303-326
166. 166 Rinne J. O., Roytta M., Paljarvi L., Rummukainen J. and Rinne U. K. (1991) Selegeline (deprenyl) treatment and death of nigral neurons in Parkinson's disease. Neurology 41: 859-861
167. 167 Tatton W. G., Ju W. Y. L., Holland D. P., Tai C. and Kwan M. (1994) (-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J. Neurochem. 63: 1572-1575
168. 168 Rojas P., Altagracia M., Kravzov J. and Rios C. (1993) Amantadine increases striatal dopamine turnover in MPTP treated mice. Drug. Dev. Res. 29: 222-226
169. 169 Stoof J. C., Booij J. Drukarch B. Amantadine as N-methyl-D-aspartic acid receptor antagonist: new possibilities for therapeutic applications? Clin. Neurol. Neurosurg. 94 (Suppl.): S4-S6
170. 170 Von Voigtlander P. F. and Moore K. E. (1971) Dopamine: release from the brain in vivo by amantadine. Science 174: 408-410
171. 171 Mizoguchi K., Yokoo H., Yoshida M., Tanaka T. and Tanaka M. (1994) Amantadine increases the extracellular dopamine levels in striatum by re-uptake inhibition and by N-methyl-D-aspartate antagonism. Brain Res. 662: 255-258
172. 172 Kornhuber J., Quack G., Dansyz W., Jellinger K., Danielczyk W., Gsell W. et al. (1995) Therapeutic brain concentration of the NMDA receptor antagonist amantadine. Neuropharmacology 34: 713-721
173. 173 Weller M., Finiels-Marlier F. and Paul S. M. (1993) NMDA receptor mediated glutamate toxicity of cultured cerebellar, cortical and mesencephalic neurons: neuroprotective properties of amantadine and memantadine. Brain. Res. 613: 143-148
174. 174 Nathanson J. A. (1977) Cyclic nucleotides and nervous system function. Physiol. Rev. 57: 157-256
175. 175 Lewis E. J, Harrington C. A. and Chikaraishi D. M. (1987) Transcriptional regulation of the tyrosine hydroxylase gene by glucocorticoid and cAMP. Proc. Natl. Acad. Sci. USA 84: 3550-3554
176. 176 Hulley P., Hartikka J., Abdel Al-S., Engels P., Buerki H. R., Wiederhold K. H. et al. (1995) Inhibitors of type IV phosphodiesterases reduce the toxicity of MPTP in substantia nigra neurons in vivo. Eur. J. Neurosci. 7: 2431-2440
177. 177 Hemmings H. C. Jr. and Greengard P. (1986) DARPP-32, a dopamine and adenosine 3′:5′-monophosphate regulated phosphoprotein: regional, tissue and phylogenetic distribution. J. Neurosci. 6: 1469-1481
178. 1 receptor and cAMP-dependent phosphorylation in Parkinson's disease. J. Neurochem. 49: 1075-1083
179. 179 Fienberg A. A., Hiroi N., Mermelstein P.G., Song W. J. et al. (1998) DARPP-32: regulator of the efficacy of dopaminergic neurotransmission. Science 281: 838-842